| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Diabetic Retinopathy - A US Market Report
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
United States |
Published |
1 June 2010 |
Number of Pages |
325 |
1-3 hours, 24 hour max |
|
Publisher |
Global Industry Analysts |
File Format |
- |
The US Diabetic Retinopathy Market will Exceed $540 Million by 2015. Diabetic retinopathy is a fashion of eye disease that occurs in people suffering from diabetes, governing to severe vision loss, and in some cases, even total blindness. Diabetic retinopathy is a collective entitle given to diverse abnormalities associated with retinal small blood vessels that are inflicted by diabetes.
Vision loss due to diabetic retinopathy is caused by pair conditions: Diabetic Macular Edema is a form of non-proliferative diabetic retinopathy where fluid enters the macula, causing it to swell and thus tend the vision blurred. Proliferative Diabetic Retinopathy is the final stage of diabetic retinopathy, in which place problems with circulation of blood cause certain retinal areas to change to ischemic (deprived of oxygen). Proliferative Diabetic Retinopathy is a major create of vision loss in patients with diabetic retinopathy.
According to Global Industry Analysts, drug therapy as antidote to diabetic retinopathy, however, is no longer a dubious proposition. Drugs of that kind as Arxxant (Eli Lilly), Atacand (Astra Zeneca), Lucentis (Genentech/Novartis), Avastin (Genetech/Roche) and Dexamethasone are every one of in their late stage development; and some of these drugs are expected to enter the market in the next few years. These drugs, when approved, would open new doors for the treatment of diabetic retinopathy, a disease that is soon being managed only by preventive measures and surgical intervention.
This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Global Industry Analysts ©
Visitor Comments
|
All posts are pre-moderated and must obey the house rules. |
|
Healthcare and Medical Company Profiles
Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.
Competitor Tracking
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
